Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by SVB Wealth LLC

SVB Wealth LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 72,315 shares of the biopharmaceutical company’s stock after selling 2,649 shares during the period. SVB Wealth LLC’s holdings in Gilead Sciences were worth $5,858,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. PCA Investment Advisory Services Inc. acquired a new position in Gilead Sciences in the second quarter worth $25,000. OFI Invest Asset Management acquired a new position in Gilead Sciences in the third quarter worth $26,000. Tompkins Financial Corp boosted its holdings in Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares during the period. Fortitude Family Office LLC acquired a new position in Gilead Sciences in the fourth quarter worth $29,000. Finally, Sanctuary Wealth Management L.L.C. acquired a new position in shares of Gilead Sciences during the fourth quarter valued at $33,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total transaction of $146,360.00. Following the completion of the transaction, the insider now directly owns 100,936 shares in the company, valued at $7,386,496.48. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.29% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on GILD shares. Royal Bank of Canada reduced their price target on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a report on Wednesday, February 14th. Cantor Fitzgerald reduced their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a report on Wednesday, February 7th. Barclays reduced their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a report on Monday, February 12th. Oppenheimer reduced their price objective on shares of Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, February 12th. Finally, StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $85.36.

Gilead Sciences Trading Down 0.6 %

Shares of NASDAQ GILD opened at $67.31 on Wednesday. The stock has a market cap of $83.81 billion, a price-to-earnings ratio of 14.96, a PEG ratio of 0.86 and a beta of 0.19. The business has a 50 day simple moving average of $72.40 and a 200 day simple moving average of $76.73. Gilead Sciences, Inc. has a 52 week low of $67.18 and a 52 week high of $87.86. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The company had revenue of $7.12 billion for the quarter, compared to the consensus estimate of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The firm’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.67 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post 7.06 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.58%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s dividend payout ratio is presently 68.44%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.